Biogen Inc. closed 41.53% short of its 52-week high of $238.00, which the company achieved on July 12th.

In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month ...

Over the course of nearly five decades, Biogen has played a major role in catalyzing and shaping Kendall Square in Cambridge, ...

While Biogen’s technology and engineering capabilities enable its high-quality medicines to come to market, its deep scientific expertise makes the firm a leader in the research and development ...

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking ...

Biogen expects 2025 revenue to decline mid-single digits as multiple sclerosis drug sales drop, partially offset by new product launches. Get access to your new suite of high-powered trading tools ...

The TRANSCEND study’s primary endpoint is the proportion of subjects who show resolution ... In September 2024, Biogen reported that the Phase II/III DEVOTE trial of high-dose Spinraza met ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other stocks. While stocks initially fell based on worries regarding Trump tariffs on America’s ...